Nutrition 21
This article was originally published in The Tan Sheet
Executive Summary
Third quarter net income increases 44% to $2.3 mil. due, in part, to settlement proceeds from patent infringement litigation, Chromax chromium picolinate maker announces April 26. Revenues for third quarter ended March 31 were $6.4 mil., down 18% from prior-year period, with reduction primarily reflecting price changes instituted in August. Core ingredients sales volume rose 51% in the quarter, while operating expenses decreased 21%, firm says
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning